Abatacept, a fusion protein directly binding to CD80/CD86, approved for second line therapy in patients with RA, has been shown to directly decrease the expression of both receptors on B cells, resulting in reduced co-stimulation of T cells (61). This evidence concerns the gene CD86 and rheumatoid arthritis.